Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 246

1.

The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.

Green JB.

Postgrad Med. 2012 Jul;124(4):54-61. doi: 10.3810/pgm.2012.07.2566. Review.

PMID:
22913894
[PubMed - indexed for MEDLINE]
2.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
[PubMed - indexed for MEDLINE]
3.

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.

Hollander PA, Kushner P.

Postgrad Med. 2010 May;122(3):71-80. doi: 10.3810/pgm.2010.05.2144.

PMID:
20463416
[PubMed - indexed for MEDLINE]
4.

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.

Campbell RK.

Ann Pharmacother. 2007 Jan;41(1):51-60. Epub 2006 Dec 26. Review.

PMID:
17190843
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
[PubMed - indexed for MEDLINE]
6.

Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.

Davidson MH.

Postgrad Med. 2014 May;126(3):56-65. doi: 10.3810/pgm.2014.05.2756. Review.

PMID:
24918792
[PubMed - indexed for MEDLINE]
7.

Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.

Del Prato S.

Int J Clin Pract Suppl. 2007 Aug;(154):38-48. Review.

PMID:
17593276
[PubMed - indexed for MEDLINE]
8.

Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

Kalra S.

J Assoc Physicians India. 2011 Apr;59:237-45. Review.

PMID:
21755761
[PubMed - indexed for MEDLINE]
9.

DPP-4 inhibitors in the treatment of type 2 diabetes.

Duez H, Cariou B, Staels B.

Biochem Pharmacol. 2012 Apr 1;83(7):823-32. doi: 10.1016/j.bcp.2011.11.028. Epub 2011 Dec 13.

PMID:
22172989
[PubMed - indexed for MEDLINE]
10.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
[PubMed - indexed for MEDLINE]
11.

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.

Chrysant SG, Chrysant GS.

Am J Cardiol. 2012 Jun 1;109(11):1681-5. doi: 10.1016/j.amjcard.2012.01.398. Epub 2012 Mar 16. Review.

PMID:
22425330
[PubMed - indexed for MEDLINE]
12.

Cardiovascular effects of the DPP-4 inhibitors.

Jose T, Inzucchi SE.

Diab Vasc Dis Res. 2012 Apr;9(2):109-16. doi: 10.1177/1479164111436236. Epub 2012 Feb 15. Review.

PMID:
22337893
[PubMed - indexed for MEDLINE]
Free Article
13.

[Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)].

Nishimura R.

Nihon Rinsho. 2012 Nov;70(11):2023-9. Review. Japanese.

PMID:
23214078
[PubMed - indexed for MEDLINE]
14.

GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.

Gallwitz B.

Handb Exp Pharmacol. 2011;(203):53-74. doi: 10.1007/978-3-642-17214-4_3. Review.

PMID:
21484567
[PubMed - indexed for MEDLINE]
15.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
[PubMed - indexed for MEDLINE]
16.

Cardiovascular biology of the incretin system.

Ussher JR, Drucker DJ.

Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8. Review.

PMID:
22323472
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

[Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors].

Avogaro A.

G Ital Cardiol (Rome). 2012 Dec;13(12 Suppl 1):23S-31S. doi: 10.1714/1203.13334. Italian.

PMID:
23258126
[PubMed - indexed for MEDLINE]
18.

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Thornberry NA, Gallwitz B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.

PMID:
19748065
[PubMed - indexed for MEDLINE]
19.

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

Freeman JS.

Cleve Clin J Med. 2009 Dec;76 Suppl 5:S12-9. doi: 10.3949/ccjm.76.s5.03. Review.

PMID:
19952298
[PubMed - indexed for MEDLINE]
Free Article
20.

Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Richard KR, Shelburne JS, Kirk JK.

Clin Ther. 2011 Nov;33(11):1609-29. doi: 10.1016/j.clinthera.2011.09.028. Epub 2011 Nov 8. Review.

PMID:
22071236
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk